Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H10N6O.ClH |
Molecular Weight | 218.644 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)\N=N\C1=C(N=CN1)C(N)=O
InChI
InChIKey=JTLLDOORGJVYPT-ASTDGNLGSA-N
InChI=1S/C6H10N6O.ClH/c1-12(2)11-10-6-4(5(7)13)8-3-9-6;/h3H,1-2H3,(H2,7,13)(H,8,9);1H/b11-10+;
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C6H10N6O |
Molecular Weight | 182.1832 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Dacarbazine (DTIC), also known as imidazole carboxamide, is an antineoplastic agent, which is used in the treatment of metastatic malignant melanoma. In addition, this drug also is indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents. Dacarbazine works by methylating guanine at the O-6 and N-7 positions. Guanine is one of the four nucleotides that makes up DNA. The alkylated DNA strands stick together such that cell division becomes impossible. This affects cancer cells more than healthy cells because cancer cells divide faster. Dacarbazine is bioactivated in liver by demethylation to "MTIC" and then to diazomethane, which is an alkylating agent. Symptoms of anorexia, nausea, and vomiting are the most frequently noted of all toxic reactions. Over 90% of patients are affected with the initial few doses.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24284332 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DTIC-DOME Approved UseDacarbazine for Injection USP is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection USP is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents. Launch Date1975 |
|||
Primary | DTIC-DOME Approved UseDacarbazine for Injection USP is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection USP is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents. Launch Date1975 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.2 μg/mL |
750 mg/m² single, intravenous dose: 750 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
DACARBAZINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.8 μM × min |
750 mg/m² single, intravenous dose: 750 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
DACARBAZINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
41.4 min |
750 mg/m² single, intravenous dose: 750 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
DACARBAZINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
95% |
DACARBAZINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1000 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 1000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 1 times / 3 weeks Co-administed with:: Lenalidomide, p.o(5 mg/day; 14 days) Sources: Page: p.503, 504 |
unhealthy, 34–79 n = 3 Health Status: unhealthy Condition: Malignant melanoma Age Group: 34–79 Sex: M+F Population Size: 3 Sources: Page: p.503, 504 |
Disc. AE: Cerebral ischemia... AEs leading to discontinuation/dose reduction: Cerebral ischemia (grade 4, 33%) Sources: Page: p.503, 504 |
800 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 800 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 1 times / 3 weeks Co-administed with:: Lenalidomide, p.o(5 mg/day; 14 days) Sources: Page: p.503 |
unhealthy, 34–79 n = 16 Health Status: unhealthy Condition: Malignant melanoma Age Group: 34–79 Sex: M+F Population Size: 16 Sources: Page: p.503 |
DLT: Thrombocytopenia... Disc. AE: Thrombocytopenia... Dose limiting toxicities: Thrombocytopenia (grade 2, 6.25%) AEs leading todiscontinuation/dose reduction: Thrombocytopenia (grade 1, 6.25%) Sources: Page: p.503 |
1000 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 1000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 1 times / 3 weeks Sources: Page: p.5 |
unhealthy, 40–65 n = 45 Health Status: unhealthy Condition: Malignant melanoma Age Group: 40–65 Sex: M+F Population Size: 45 Sources: Page: p.5 |
Other AEs: Neutropenia, Fatigue... Other AEs: Neutropenia (grade 4, 2.2%) Sources: Page: p.5Fatigue (grade 4, 2.2%) |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Disc. AE: Leukopenia, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Leukopenia (grade 3-5) Sources: Thrombocytopenia (grade 3-5) Anemia (sometimes) Hematopoiesis impaired Hepatotoxicity (grade 3-5, 0.01%) Hepatic vein thrombosis (grade 3-5, 0.01%) Necrosis hepatocellular (grade 3-5, 0.01%) Anaphylaxis |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Disc. AE: Anemia, Leukopenia... AEs leading to discontinuation/dose reduction: Anemia (mild) Sources: Leukopenia (grade 3-5) Thrombocytopenia (grade 3-5) Hepatotoxicity (grade 3-5) Hepatic vein thrombosis (grade 3-5) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cerebral ischemia | grade 4, 33% Disc. AE |
1000 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 1000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 1 times / 3 weeks Co-administed with:: Lenalidomide, p.o(5 mg/day; 14 days) Sources: Page: p.503, 504 |
unhealthy, 34–79 n = 3 Health Status: unhealthy Condition: Malignant melanoma Age Group: 34–79 Sex: M+F Population Size: 3 Sources: Page: p.503, 504 |
Thrombocytopenia | grade 1, 6.25% Disc. AE |
800 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 800 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 1 times / 3 weeks Co-administed with:: Lenalidomide, p.o(5 mg/day; 14 days) Sources: Page: p.503 |
unhealthy, 34–79 n = 16 Health Status: unhealthy Condition: Malignant melanoma Age Group: 34–79 Sex: M+F Population Size: 16 Sources: Page: p.503 |
Thrombocytopenia | grade 2, 6.25% DLT |
800 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 800 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 1 times / 3 weeks Co-administed with:: Lenalidomide, p.o(5 mg/day; 14 days) Sources: Page: p.503 |
unhealthy, 34–79 n = 16 Health Status: unhealthy Condition: Malignant melanoma Age Group: 34–79 Sex: M+F Population Size: 16 Sources: Page: p.503 |
Fatigue | grade 4, 2.2% | 1000 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 1000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 1 times / 3 weeks Sources: Page: p.5 |
unhealthy, 40–65 n = 45 Health Status: unhealthy Condition: Malignant melanoma Age Group: 40–65 Sex: M+F Population Size: 45 Sources: Page: p.5 |
Neutropenia | grade 4, 2.2% | 1000 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 1000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 1 times / 3 weeks Sources: Page: p.5 |
unhealthy, 40–65 n = 45 Health Status: unhealthy Condition: Malignant melanoma Age Group: 40–65 Sex: M+F Population Size: 45 Sources: Page: p.5 |
Anaphylaxis | Disc. AE | 250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Hematopoiesis impaired | Disc. AE | 250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Hepatic vein thrombosis | grade 3-5, 0.01% Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Hepatotoxicity | grade 3-5, 0.01% Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Necrosis hepatocellular | grade 3-5, 0.01% Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Leukopenia | grade 3-5 Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Thrombocytopenia | grade 3-5 Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Anemia | sometimes Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Hepatic vein thrombosis | grade 3-5 Disc. AE |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Hepatotoxicity | grade 3-5 Disc. AE |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Leukopenia | grade 3-5 Disc. AE |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Thrombocytopenia | grade 3-5 Disc. AE |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Anemia | mild Disc. AE |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 208.0 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 2195.0 |
no | |||
Page: 2195.0 |
no | |||
Page: abstract |
yes | |||
Page: abstract |
yes | |||
Page: abstract |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin. | 1975 Nov |
|
[DTIC: effect on fibrinolysis and thrombocyte function]. | 1986 Oct |
|
Peripheral DTIC neurotoxicity: a case report. | 1987 |
|
Fatal hepatic vascular toxicity of DTIC. Is it really a rare event? | 1988 May 15 |
|
[Hepatic veno-occlusive disease caused by Deticene: a cause of acute hypovolemic shock]. | 1990 |
|
Dana-Farber Cancer Institute studies in advanced sarcoma. | 1990 Feb |
|
Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3-gallate and dacarbazine in mice. | 2001 |
|
Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. | 2001 Dec |
|
Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma. | 2001 Jul-Aug |
|
Docetaxel in combination with dacarbazine in patients with advanced melanoma. | 2002 |
|
Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha. | 2002 Dec |
|
Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study. | 2002 Oct |
|
Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response. | 2002 Oct |
|
IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC. | 2003 |
|
Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. | 2003 Aug |
|
Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer. | 2003 Feb 20 |
|
Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma. | 2003 Jan 13 |
|
O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. | 2003 Oct 20 |
|
[Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma]. | 2004 |
|
Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations. | 2004 Apr 1 |
|
Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma. | 2004 Dec |
|
Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. | 2004 Dec |
|
Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma. | 2004 Jun |
|
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. | 2004 Jun 1 |
|
Correspondence re: DC Lev et al., Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther, 2003;2(8):753-63. | 2004 Mar |
|
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. | 2004 Mar 15 |
|
Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model. | 2005 Aug |
|
Combined chemoimmunotherapy of metastatic melanoma: a single institution experience. | 2005 Jun |
|
Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma. | 2005 Nov |
|
Sarcomatoid renal cell carcinoma with a chromophobe component producing beta-human chorionic gonadotropin. | 2005 Sep |
|
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. | 2005 Sep 20 |
|
Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial. | 2006 |
|
Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model. | 2006 Dec |
|
[Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma]. | 2006 Feb |
|
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. | 2006 Jul 1 |
|
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. | 2006 Oct 10 |
|
Intralesional therapy of metastatic spreading melanoma with beta-interferon. | 2006 Sep |
|
Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting. | 2007 |
|
Hemorrhagic cystitis in a patient receiving conventional doses of dacarbazine for metastatic malignant melanoma: case report and review of the literature. | 2007 Jun |
|
Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. | 2007 Oct |
|
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. | 2007 Sep 1 |
|
Influence of therapy on the antioxidant status in patients with melanoma. | 2008 Apr |
|
The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas. | 2008 Apr |
|
Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma. | 2008 Feb |
|
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. | 2008 Feb 20 |
|
Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. | 2008 Jun |
|
Cerebellar dysfunction caused by procarbazine and consumption of excessive amount of bananas. | 2008 Jun |
|
Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/c-Jun NH2-terminal kinase activation in human melanoma cells. | 2008 Mar |
|
Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. | 2009 Jun |
|
Glucocorticoid-dependent expression of O(6)-methylguanine-DNA methyltransferase gene modulates dacarbazine-induced hepatotoxicity in mice. | 2010 Jun |
Patents
Sample Use Guides
Malignant Melanoma: the recommended dosage is 2 to 4.5 mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals
Hodgkin's Disease: The recommended dosage of Dacarbazine for Injection, USP in the treatment of Hodgkin’s disease is 150 mg/square meter body surface/day for 5 days, in combination with other effective drugs. Treatment may be repeated every 4 weeks.5 An alternative recommended dosage is 375 mg/square meter body surface on day 1, in combination with other effective drugs, to be repeated every 15 days
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21868520
The effect of alkyating agent dacarbazine (DTIC) and imexon, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). Growth inhibition in vitro was additive with the two drugs. There was no effect on drug uptake or on the number of DNA strand breaks. There was a >75% reduction in cellular glutathione and cysteine with imexon but not DTIC. Co-administration of the two drugs in mice caused an increase in the area under the curve of both drugs, but the combination was not effective in reducing human A375 melanoma tumors in vivo.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:18:27 GMT 2023
by
admin
on
Sat Dec 16 08:18:27 GMT 2023
|
Record UNII |
IBG90R0OVS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
IBG90R0OVS
Created by
admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
|
PRIMARY | |||
|
17925-90-5
Created by
admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
|
PRIMARY | |||
|
135565185
Created by
admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
|
PRIMARY | |||
|
21299-67-2
Created by
admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |